10 Anti-Obesity Drugs: Launched & In Clinical Trials

Recently Launched / Approved Drugs

1. Wegovy (Semaglutide)
   • Company: Novo Nordisk
   • Mechanism: GLP-1 receptor agonist
   • Status: Approved by FDA (2021)
   • Notes: Weekly injection. Highly effective in reducing body weight (~15%).
2. Zepbound (Tirzepatide)
   • Company: Eli Lilly
   • Mechanism: Dual GLP-1/GIP receptor agonist
   • Status: Approved by FDA (Nov 2023)
   • Notes: Higher weight loss efficacy than semaglutide.
3. Orforglipron (LY3502970)
   • Company: Eli Lilly
   • Mechanism: Oral GLP-1 receptor agonist
   • Status: In Phase 3 (as of 2024)
   • Notes: First oral GLP-1 with promising results.
4. Retatrutide
   • Company: Eli Lilly
   • Mechanism: Triple agonist (GLP-1, GIP, glucagon)
   • Status: Phase 2 completed; entering Phase 3
   • Notes: Showed up to 24% weight loss in trials.
5. Cagrilintide + Semaglutide
   • Company: Novo Nordisk
   • Mechanism: Amylin analog + GLP-1 combo
   • Status: Phase 3 (AMPLITUDE trials)
   • Notes: Dual-hormone approach, under high interest.

🧬 In Clinical Trials or Experimental

6. Bimagrumab
   • Company: Novartis (previously developed with MorphoSys)
   • Mechanism: Anti-activin type II receptor antibody (builds muscle, reduces fat)
   • Status: Early-stage; studies in obese patients with type 2 diabetes.
   • Notes: Unique approach — increases lean mass while reducing fat.
7. Pf-07258669
   • Company: Pfizer
   • Mechanism: Oral GLP-1 receptor agonist
   • Status: In early-stage clinical trials (Phase 1/2)
   • Notes: Competing with Eli Lilly’s oral GLP-1 drugs.
8. RZL-012
   • Company: Raziel Therapeutics
   • Mechanism: Fat tissue reduction via chemical lipolysis (localized)
   • Status: Phase 2 trials
   • Notes: Targeted fat loss (e.g., submental area), not for generalized obesity.
9. VK2735
   • Company: Viking Therapeutics
   • Mechanism: Dual GLP-1/GIP agonist
   • Status: Phase 2 initiated in 2024
   • Notes: Competing with tirzepatide; early data looks promising.
10. GEP44 (multi-pathway peptide)

• Institution: Academic research (preclinical trials)
• Mechanism: Simultaneous targeting of multiple gut hormones (GLP-1, Y2, etc.)
• Status: Preclinical
• Notes: Aims to minimize side effects while maximizing weight loss.

Summary:

⚠️ Note & Disclaimer

This list includes both approved and experimental drugs. We are not promoting any specific medication. Always consult with a qualified healthcare provider before considering any weight loss therapy.